Regenerative Medicine Today welcomes Thomas Tillett, who is the founding President and CEO of RheoGene. Under Mr. Tillett’s leadership, RheoGene established an innovative clinical development program with the RheoSwitch ™ Therapeutic System that has led to the first human clinical trial of a small molecule induced gene regulation system.
A Phase I clinical trial for melanoma was started in 2008. This represents a major advance for gene therapy therapeutics that offers the potential for significant improvements in safer and more controllable forms of gene therapy. RheoGene also received a $4.3 million grant from the Michael J. Fox Foundation to support the development of a novel therapeutic for Parkinson’s disease.
Mr. Tillett also led the successful merger of RheoGene Inc. with Intrexon Corporation at the beginning of 2007.
Host John Murphy.
For more information about the McGowan Institute for Regenerative Medicine, visit:
McGowan Institute Research Site
McGowan Institute Patient Site
McGowan Institute on Facebook
McGowan Institute on Twitter